A blood test that can detect more than 50 types of cancer before any clinical signs or symptom of the disease has been developed by scientists.
The test is based on a type of DNA that is shed by tumours into the bloodstream known as cell-free DNA (cfDNA).
The researchers, including scientists from The Francis Crick Institute and University College London, said this method can not only tell whether someone has cancer, but also the type of cancer they have.
They believe the findings, published in the journal Annals of Oncology could in future help in the early diagnosis and treatment of tumours.
But experts say more work is needed to improve the test.
Commenting on the research, Dr David Crosby, head of early detection at Cancer Research UK, who was not involved in the study, said: “Although this test is still at an early stage of development, the initial results are encouraging.
“And if the test can be fine-tuned to be more efficient at catching cancers in their earliest stages, it could become a tool for early detection.
“But more research is needed to improve the test’s ability to catch early cancers and we still need to explore how it might work in a real cancer screening scenario.”
The test uses machine learning algorithms to look for chemical changes, called methylation, in cfDNA, which can contribute to tumour growth.
The researchers used the method on 4,316 samples – some with and some without cancer.
More than 50 types of cancer, such as pancreatic, lung and ovarian, were included in the study.
The test was able to predict the tissue in which the cancer originated in 96% of samples, and it was accurate in 93%, the researchers said.
Dr Michael Seiden, president of US Oncology in Texas, and senior author on the study, said the results showed that “targeted methylation” could be used for screening at population level.
He added: “Considering the burden of cancer in our society, it is important that we continue to explore the possibility that this test might intercept cancers at an earlier stage and, by extension, potentially reduce deaths from cancers for which screening is either not available or has poor adherence.”
– The study was funded by US-based company Grail Inc, maker of the blood test.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here